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Introduction {#sec005}
============

Hospital-acquired infections (HAIs) are a major cause of nosocomial morbidity and mortality. While ongoing prevention programs are indeed necessary, our understanding of the underlying mechanisms that facilitate and ultimately trigger HAIs remains insufficient to effectively address the problem at hand. Existing strategies have primarily focused on attenuating the effects of extrinsic stressors on the host´s immune system (e.g., careful regulation of operating-theatre temperatures, limitation of blood transfusions to reasonable minimums, and shortening surgery times). These strategies seek to modify factors external to the host. While helpful, at best they only enable a modest reduction in postoperative infection rates \[[@pone.0230336.ref001],[@pone.0230336.ref002]\].

To our knowledge, few studies have investigated methods that optimize natural host responses to infection in the perioperative setting. One potential point of intervention that has recently attracted attention is the immunological role of vitamin D. Vitamin D receptors are known to be present in most immune system cells, including macrophages, B and T lymphocytes, and neutrophils, and vitamin D regulates the gene expression of antimicrobial peptides as part of the innate immune response \[[@pone.0230336.ref003]--[@pone.0230336.ref007]\].

A growing body of evidence indicates that vitamin D-deficient patients are more susceptible to nosocomial infections (HAIs) such as pneumonia, urinary tract infections, sepsis, and central line infections \[[@pone.0230336.ref001]\].

Some studies performed in critically ill patients admitted to an intensive care unit (ICU) suggest that severe vitamin D deficiency before admission is associated with acute kidney injury and mortality \[[@pone.0230336.ref008]\]. While several reports point to a link between lower vitamin D levels and an increased risk of postoperative HAIs \[[@pone.0230336.ref001]--[@pone.0230336.ref003],[@pone.0230336.ref009]\], the influence of vitamin D on surgical outcomes remains unknown. Quaraishi and coworkers reported a significant inverse association between vitamin D levels and HAI risk in bariatric surgery patients \[[@pone.0230336.ref002]\]. In line with this finding, Turan et al reported an increased risk of HAI and serious complications after noncardiac surgery \[[@pone.0230336.ref003]\]. Some recent studies have examined the link between surgical site infection (SSI) and preoperative 25-hydroxyvitamin D levels. Abdehgah and coworkers found that vitamin D levels had a strong effect on SSI, but concluded that double-blind trials were needed to confirm this association relationship \[[@pone.0230336.ref010]\].

The aim of this study was to assess the possible association between serum vitamin D levels and HAIs in patients that had undergone hepatobiliary surgery in a third-level hospital.

Materials and methods {#sec006}
=====================

Patients and ethics statement {#sec007}
-----------------------------

Upon receiving approval from CEICA (The Research Ethics Committee of Aragon, Spain) we performed a prospective analytical observational study of hepatobiliary surgery patients from a third-level hospital in Aragon, Spain. All participating patients were informed in our outpatient clinic about the main study outcomes. CEICA waived the requirement for written informed consent. Patients were free to withdraw consent at any time during the study, although none chose to do so.

Upon agreement to participate in the study, patient data were anonymized by the lead investigator. Neither collaborators nor statisticians had access to non-anonymized data.

Analyses were restricted to patients who underwent hepatobiliopancreatic surgery between February 2018 and March 2019 in the General and Digestive Surgery Service of the Miguel Servet Hospital (Aragon, Spain). Patients who underwent any other type of surgery and those who were admitted but did not undergo surgery due to the presence of unresectable tumours or life-threatening comorbidities were excluded.

Vitamin D assays {#sec008}
----------------

Vitamin D concentrations were measured from serum samples obtained at admission, the day before surgery, and were analysed in our biochemistry laboratory by chemiluminescent microparticle immunoassay (CMIA) using an Alinity i ® Analizer as previously described \[[@pone.0230336.ref007]\].

CMIA analysis uses paramagnetic microparticles coated with anti-vitamin D antibodies to separate the vitamin from its binding protein. Next, the vitamin D conjugate (vitamin D+paramagnetic microparticles) is labelled with acridinium to create a chemiluminescent reaction, which is measured in relative light units (RLU). There is an inverse association between the amount of 25-hydroxyvitamin D and the RLU detected by the system \[[@pone.0230336.ref007]\].

There is some debate regarding optimal vitamin D levels. The Institute of Medicine recommends 25(OH)D levels \>20 ng/ml (50 nmol/L), while the American Endocrine Society considers levels \>30 ng/ml (75 nmol/L) as optimal, since levels in this range allow maximum calcium absorption from the gut while avoiding hyperparathyroidism \[[@pone.0230336.ref011]--[@pone.0230336.ref015]\]. Because the Endrocrine Service of our hospital adheres to the guidelines of the American Endocrine Society, we considered levels \>30 ng/ml (75 nmol/L) as normal, while levels of 20--30 ng/ml (50--75 nmol/L) and \<20 ng/ml (\<50 nmol/L) were considered indicative of insufficiency and deficiency, respectively.

Data collection and statistical analysis {#sec009}
----------------------------------------

During the course of the study, HAIs acquired by participating patients were documented from admission to discharge and subsequently via scheduled outpatient review appointments. HAIs were diagnosed according to the diagnostic criteria of the Centers for Disease Control and Prevention (CDC) \[[@pone.0230336.ref016]\]. Cell culture and microorganism identification was performed by hospital's microbiology service.

The information recorded in the study anonymized database included patient demographics, comorbidities, Charlson index score \[[@pone.0230336.ref017],[@pone.0230336.ref018]\], type of procedure and duration, use of transfusions and/or vasopressors, ICU admission, length of stay, Clavien Dindo classification \[[@pone.0230336.ref019]\], reintervention, readmission, and mortality rates.

Categorical variables were expressed as frequency distributions and continuous variables as the median and standard deviation. We used the Shapiro-Wilk test to confirm normal distribution of continuous variables. Distribution was considered normal at p-values \>0.05. The Student-Fisher t-test or Mann-Whitney U-test were used for analyses involving 2 continuous quantitative variables, and ANOVA or the Kruskal-Wallis H-test for analyses involving 3 continuous quantitative variables. Categorical variables were analysed using the Chi squared test with a Yates correction. In cases in which the grouping variable had 3 categories, means were compared by ANOVA for continuous variables. Paired (post-hoc) comparisons were performed using Tukey's test for parametric variables or the Benjamini & Hochberg method in cases in which the explanatory variable had a non-normal distribution. Finally, logistic regression analysis was performed to calculate the odds ratio, with the occurrence/absence of the event of interest as the dependent variable and parameters of interest as the independent variable(s). A Wald test was used to calculate the significance of each coefficient in the model. P-values \<0.05 were considered statistically significant. In all cases two-sided P-values are reported. Sample size was limited by the recruitment capacity of the hepatobiliary surgery unit. All statistical analyses was performed using R v.3.1.3 statistical software.

Results {#sec010}
=======

Our study population consisted of 301 patients; 169 men (56.1%) and 132 women (43.9%). The mean 25-hydroxyvitamin D concentration was 38.56 nmol/L, which corresponds to vitamin D deficiency (vitamin D deficiency, \<50 nmol/L; vitamin D insufficiency, 50--75 nmol/L; optimal vitamin D concentration, \>75 nmol/L). [Table 1](#pone.0230336.t001){ref-type="table"} shows summary statistics for baseline demographic data, stratified according to serum vitamin D concentrations and expressed as tertiles. The Charlson comorbidity index is a summative score based on concurrent clinical conditions in a given patient \[[@pone.0230336.ref017]\].

10.1371/journal.pone.0230336.t001

###### Demographic data and baseline medical conditions for 301 patients, stratified by tertiles (T) of serum vitamin D concentration.

![](pone.0230336.t001){#pone.0230336.t001g}

                                 \[Study Population\]   T1 \[8.8,25.5\]   T2 (25.5,43.3\]   T3 (43.3,233\]   P-value
  ------------------------------ ---------------------- ----------------- ----------------- ---------------- ---------
  N                              301                    102               99                100              
  Sex:                                                                                                       \<0.001
      Males                      169 (56.1%)            49 (48.0%)        74 (74.7%)        46 (46.0%)       
      Females                    132 (43.9%)            53 (52.0%)        25 (25.3%)        54 (54.0%)       
  Age                            65.4 (12.7)            68.0 (11.0)       66.3 (12.0)       62.0 (14.2)      0.002
  Diabetes                       61 (20.3%)             23 (22.5%)        24 (24.2%)        14 (14.0%)       0.155
  Hypertension                   151 (50.2%)            50 (49.0%)        59 (59.6%)        42 (42.0%)       0.044
  COPD                           26 (8.64%)             13 (12.7%)        9 (9.09%)         4 (4.00%)        0.085
  Cardiovascular disease         50 (16.6%)             21 (20.6%)        16 (16.2%)        13 (13.0%)       0.346
  Obesity                        82 (27.2%)             26 (25.5%)        27 (27.3%)        29 (29.0%)       0.855
  [ASA index:]{.ul}                                                                                          0.002
  1                              42 (14.0%)             9 (8.82%)         9 (9.09%)         24 (24.0%)       
  2                              150 (49.8%)            51 (50.0%)        47 (47.5%)        52 (52.0%)       
  3--4                           109 (36.2%)            42 (41.2%)        43 (43.4%)        24 (24.0%)       
  Charlson Index Score:                                                                                      0.003
  0                              19 (6.31%)             4 (3.92%)         4 (4.04%)         11 (11.0%)       
  1                              17 (5.65%)             4 (3.92%)         2 (2.02%)         11 (11.0%)       
  2                              15 (4.98%)             3 (2.94%)         3 (3.03%)         9 (9.00%)        
  3                              36 (12.0%)             13 (12.7%)        10 (10.1%)        13 (13.0%)       
  +4                             214 (71.1%)            78 (76.5%)        80 (80.8%)        56 (56.0%)       
  Intervention:                                                                                              0.713
      Minor hepatectomy          77 (25.6%)             28 (27.5%)        27 (27.3%)        22 (22.0%)       
  Major hepatectomy              40 (13.3%)             12 (11.8%)        12 (12.1%)        16 (16.0%)       
  Pancreaticoduodenectomy        36 (12.0%)             17 (16.7%)        12 (12.1%)        7 (7.00%)        
      Distal pancreatectomy      10 (3.32%)             3 (2.94%)         3 (3.03%)         4 (4.00%)        
      Cholecystectomy            106 (35.2%)            32 (31.4%)        33 (33.3%)        41 (41.0%)       
      Exploratory laparotomy     27 (8.97%)             9 (8.82%)         9 (9.09%)         9 (9.00%)        
      Others                     5 (1.66%)              1 (0.98%)         3 (3.03%)         1 (1.00%)        
  Duration                       203 (93.7)             214 (97.7)        207 (97.4)        188 (84.2)       0.116
  Clavien Dindo Classification                                                                               0.031
  0                              121 (40.2%)            37 (36.3%)        39 (39.4%)        45 (45.0%)       
  1                              27 (8.97%)             7 (6.86%)         5 (5.05%)         15 (15.0%)       
  2                              50 (16.6%)             13 (12.7%)        21 (21.2%)        16 (16.0%)       
  3                              73 (24.3%)             28 (27.5%)        25 (25.3%)        20 (20.0%)       
  4                              18 (5.98%)             9 (8.82%)         6 (6.06%)         3 (3.00%)        
  5                              12 (3.99%)             8 (7.84%)         3 (3.03%)         1 (1.00%)        

We divided the sample in tertiles according to vitamin D concentrations so as to obtain a balanced stratification with our reduced sample size. Abbreviations: N,number of patients; T1, first tertile; T2, second tertile; T3, third tertile; COPD, Chronic Obstructive Pulmonary Disease; ASA, American Society of Anesthesiologists.

Vitamin D levels were significantly higher in female than male patients (p = 0.001), accounting for 54% of the third tertile. Mean age was 65.4 years, and vitamin D levels decreased with increasing age (p = 0.002). No significant differences in serum vitamin D levels were associated with the presence of the following comorbidities: diabetes (p = 0.155), chronic obstructive pulmonary disease (COPD) (p = 0.085), cardiovascular disease (p = 0.346), and obesity (p = 0.855). However, we observed a significant association between comorbid hypertension and serum vitamin D levels, which were suboptimal in hypertensive patients. Although most of our patients (49.8%) scored II according to the American Society of Anesthesiology (ASA) patient classification rating, patients with higher ASA (p = 0.002) and Charlson (p = 0.003) scores, had lower serum vitamin D levels.

The most common interventions undergone by patients were cholecystectomy (n = 106, 32%) and minor and major hepatectomies (25.6% and 13.3% respectively). We observed no significant differences in vitamin D levels according to intervention type, although patients that had undergone cholecystectomy had the highest levels of vitamin D. Surgery duration was not associated with any differences in vitamin D levels (p = 0.116).

Patient status according to the Clavien Dindo classification of postoperative complications was associated with significant differences in vitamin D levels (p = 0.031). Patients in the first tertile accounted for almost half of all patients with a Clavien Dindo score \>2 points. More than 55% of patients in the third tertile had a Clavien Dindo score of 0 or 1 ([Table 1](#pone.0230336.t001){ref-type="table"}).

Higher vitamin D concentrations were associated with a decreased odds ratio for HAIs in general (p = 0.014), and in particular for surgical site infection (p = 0.026) and central line infection (p = 0.037). For each 26.2 nmol/L increase in vitamin D level the risk of HAI decreased by 34%. Higher vitamin D concentrations were also associated with lower rates of reoperation (p = 0.039), mortality (p = 0.025), and ICU admission (p = 0.005). However we observed no significant association between higher vitamin D concentrations and health care-associated pneumonia (HCAP) (p = 0.089), urinary tract infection (UTI) (p = 0.686), or hospital re-admission (p = 0.828) ([Table 2](#pone.0230336.t002){ref-type="table"}). The estimated common effect odds ratio (OR) for vitamin D levels across individual in-hospital outcomes was 0.67 (CI 0.51--0.88, p = 0.005) for a 26.2 nmol/L increase in vitamin D level.

10.1371/journal.pone.0230336.t002

###### Associations between serum vitamin D concentration and In-hospital outcomes.
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  *In-Hospital Outcome*    *Incidence N(%)*   *OR (CI 2.5--97.5%)*   *P-value (Wald)*
  ------------------------ ------------------ ---------------------- ------------------
  *HAIs*                   91 (28.3)          0.66 (0.48--0.92)      *0.014*
  *UTI*                    6 (1.9)            0.81 (0.28--2.29)      *0.686*
  *SSI*                    83 (25.9)          0.68 (0.49--0.96)      *0.026*
  *HCAP*                   9 (2.8)            0.33 (0.09--1.18)      *0.089*
  *CAI*                    13 (4)             0.32 (0.11--0.94)      *0.037*
  *ICU*                    129 (40.2)         0.65 (0.49--0.88)      *0.005*
  *Reintervention*         32 (10)            0.54 (0.3--0.97)       *0.039*
  *Re-admission*           32 (10)            0.96 (0.63--1.45)      *0.828*
  *Transfusions*           53 (16.9)          0.45 (0.28--0.75)      *0.002*
  *Vasopressors*           38 (12.1)          0.34 (0.18--0.65)      *0.001*
  *Mortality*              13 (4.1)           0.27 (0.09--0.85)      *0.025*
  *In-hospital outcomes*   *163 (50.8)*       *0.67 (0.51--0.88)*    *0.005*

Logistic regression analysis was performed to determine the odds ratio (OR) for increasing 25(OH)D from the lower quartile (21.5 nmol/L) to the upper quartile (47.7 nmol/L). Abbreviations: CI, confidence interval; CAI, catheter associated bloodstream infections; HAI, hospital-acquired infection; HCAP, health-care associated pneumonia; ICU, intensive care unit; N, number of patients; UTI, urinary tract infection; SSI, surgical site infection.

The estimated odds of developing a HAI decreased almost linearly with increasing vitamin D concentration when all data points were plotted, although 93.02% of patients had vitamin D values \<75 nmol/L ([Fig 1](#pone.0230336.g001){ref-type="fig"}).

![Risk of in-hospital morbidity/mortality (in log odds) versus vitamin D concentration.\
This figure depicts the risk in-hospital morbidity/mortality (log odds) as a function of vitamin D concentration. We observed that the log odds value decreases as vitamin D concentration increases. Probabilities were estimated using a logistic regression model.](pone.0230336.g001){#pone.0230336.g001}

In patients with vitamin D levels \<25 nmol/L the odds ratio for HAI was significantly lower than that of patients with vitamin D levels \>43.3 nmol/L, but did not differ to that of patients with vitamin D levels within the 25.5--43.3 nmol/L range ([Fig 2](#pone.0230336.g002){ref-type="fig"}).

![Raw odds ratios (95% CI) of each tertile of 25(OH)D for in-hospital morbidity/mortality.\
Figure shows the odds ratio (yellow dots) and confidence interval (horizontal lines) for in-hospital outcomes for each tertile, using the first tertile as a reference. The odds versus patients with vitamin D \<25 nmol/L (reference category) were significantly lower in patients with vitamin D \> 43.3 nmol/L, while the odds did not differ significantly in patients with vitamin D 25(OH)D in the range 25.5--43.3 nmol/L.](pone.0230336.g002){#pone.0230336.g002}

The age, sex, and Charlson index-adjusted model \[[@pone.0230336.ref011],[@pone.0230336.ref012]\] ([Table 3](#pone.0230336.t003){ref-type="table"}) revealed that higher vitamin D levels were associated with a 29% reduction (OR 0.71, p = 0.054) in nosocomial infections and a 70% reduction in mortality (OR 0.3, p = 0.056), although these effects were not significant. However, the odds ratio for central line infections was significantly lower in this patient group (OR 0.23, p = 0.023). The model also revealed that the need for transfusions (OR 0.44, p = 0.04) and vasopressors (OR 0.36, p = 0.04) was significantly lower in patients with higher levels of vitamin D. Total in-hospital outcomes were also reduced in this group, with a near insignificant OR of 0.67 (CI 0.51--0.88, p = 0.05).

10.1371/journal.pone.0230336.t003

###### Associations between serum vitamin D concentration and In-Hospital outcomes.
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  *In-Hospital Outcomes*   *Incidence N(%)*   *OR (CI 2.5%-97.5%)*   *P-value (Wald)*
  ------------------------ ------------------ ---------------------- ------------------
  *HAIs*                   91 (28.3)          0.71 (0.5--1.01)       *0.054*
  *UTI*                    6 (1.9)            0.87 (0.4--1.89)       *0.734*
  *SSI*                    83 (25.9)          0.74 (0.53--1.05)      *0.097*
  *HCAP*                   9 (2.8)            0.36 (0.09--1.38)      *0.135*
  *CAI*                    13 (4)             0.23 (0.06--0.82)      *0.023*
  *ICU admission*          129 (40.2)         0.71 (0.52--0.98)      *0.04*
  *Reintervention*         32 (10)            0.6 (0.33--1.1)        *0.098*
  *Re-admission*           32 (10)            1 (0.65--1.53)         *0.995*
  *Transfusions*           53 (16.9)          0.44 (0.25--0.78)      *0.004*
  *Vasopressors*           38 (12.1)          0.36 (0.18--0.73)      *0.004*
  *Mortality*              13 (4.1)           0.3 (0.09--1.03)       *0.056*
  *In-hospital outcomes*   *163 (50.8)*       *0.75 (0.56--1)*       *0.05*

Multivariate model adjusted for sex, age and Charlson comorbidity index. Odds ratios (OR) were estimated for increasing 25(OH)D concentrations from the lower quartile (21.5 nmol/L) to the upper quartile (47.7 nmol/L). Abbreviations: CI, confidence interval; CAI, catheter-associated bloodstream infection; HAI, hospital-acquired infection; HCAP, health-care associated pneumonia; ICU, intensive care unit; N, number of patients; UTI, urinary tract infection; SSI, surgical site infection.

Multivariate analysis of HAI risk according to vitamin D tertiles adjusted for sex, age, ASA, Charlson index, and surgery type (emergency vs planned) ([Table 4](#pone.0230336.t004){ref-type="table"}) revealed significant differences, with patients in the first tertile at greater risk of acquiring nosocomial infections than those in the third tertile. However, after adjustment for sex, age, transfusions, vasopressors, surgery duration, and length of stay no significant differences were observed between the first and either the second or third tertiles ([Table 5](#pone.0230336.t005){ref-type="table"}).

10.1371/journal.pone.0230336.t004

###### Multivariate analysis to estimate the risk (odds ratio) of developing a HAI according to vitamin D concentration, expressed in tertiles and adjusted for sex, age, ASA, Charlson index score, and surgery type (emergency vs planned).
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                           OR      CI (2.5%)   CI (97.5%)   P-value
  ------------------------ ------- ----------- ------------ ---------
  T1 \[8.8,25.5nmol/L\]    1       \-          \-           \-
  T2 (25.5,43.3 nmol/L\]   0.543   0.283       1.025        0.062
  T3 (43.3,233 nmol/L\]    0.476   0.236       0.94         0.035

Abbreviations: CI, confidence interval; OR, odds ratio; T1, first tertile; T2, second tertile; T3, third tertile.

10.1371/journal.pone.0230336.t005

###### Results of multivariate analysis to estimate the risk (odds ratio) of developing a HAI according to vitamin D concentration, expressed in tertiles and adjusted for sex, age, transfusions, vasopressors, surgery duration, and length of stay.
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                           OR      CI (2.5%)   CI (97.5%)   P-value
  ------------------------ ------- ----------- ------------ ---------
  T1 \[8.8,25.5nmol/L\]    1       \-          \-           \-
  T2 (25.5,43.3 nmol/L\]   0.706   0.301       1.65         0.42
  T3 (43.3,233 nmol/L\]    0.908   0.398       2.091        0.818

Abbreviations: CI, confidence interval; OR, odds ratio; T1, first tertile; T2, second tertile; T3, third tertile.

Discussion {#sec011}
==========

Vitamin D deficiency is a worldwide pandemic involving both lifestyle- and nutrition-related factors. Even in Spain, where weather conditions could be assumed to facilitate vitamin D metabolism, studies have revealed a paradoxical hypovitaminosis, which cannot be compensated for by mere exposure to sunlight \[[@pone.0230336.ref011],[@pone.0230336.ref012],[@pone.0230336.ref020]\]. The subject of optimal vitamin D serum levels is the focus of an ongoing interdisciplinary debate. The most accepted definition of vitamin D deficiency is a 25-hydroxyvitamin D concentration of less than 50 nmol/L, while insufficiency is diagnosed at concentrations of 50--75 nmol/L \[[@pone.0230336.ref013],[@pone.0230336.ref015],[@pone.0230336.ref020],[@pone.0230336.ref021]\]. According to these criteria, more than 90% of our study population was either vitamin D deficient or insufficient.

Dividing our sample into tertiles creates a heterogeneous third tertile that includes patients with mild insufficiency and those with optimal vitamin D levels. However, we applied this approach on the basis that our population was insufficiently large to create more categories without losing statistical power.

Recent years have seen an improvement in our understanding of the ways in which vitamin D contributes to vital physiological processes, in addition to its "traditional" role in skeletal metabolism. In their 2012 review of HAIs and vitamin D serum levels, Youssef et al. concluded that patients with vitamin D deficiency had higher rates of infection and that vitamin D levels should be checked upon hospital admission to correct insufficiency \[[@pone.0230336.ref001]\].

Low vitamin D concentrations are also associated with inflammation, increased risk of cardiovascular disease, and higher insulin resistance and all-cause mortality, especially cardiovascular mortality, given the association between vitamin D deficiency and increased arterial stiffness and endothelial dysfunction in human blood vessels. This association has also been demonstrated in critically ill patients \[[@pone.0230336.ref003],[@pone.0230336.ref006],[@pone.0230336.ref007],[@pone.0230336.ref022]--[@pone.0230336.ref026]\].

We observed no association between cardiovascular disease and lower vitamin D levels, a consequence of the sample size, study design, and study population. However, we did observe an association between lower vitamin D levels and hypertension (p = 0.044). In line with the fact that patients with low vitamin D serum levels tend to be high-risk patients with multiple comorbidities, ASA (p = 0.002) and Charlson index (p = 0.003) scores were higher in these patients. We detected no significant associations between vitamin D levels and comorbid diabetes, obesity, or COPD (p\>0.005).

Quaraishi and coworkers studied the specific link between vitamin D concentrations and HAIs in surgical patients. In their retrospective analysis of bariatric surgery patients, the authors reported a significant inverse association between preoperative 25 (OH)D levels and the risk of HAI. Several studies have also reported decreased vitamin D bioavailability in obese patients due to sequestration of this fat-soluble vitamin in adipose tissue \[[@pone.0230336.ref002],[@pone.0230336.ref027],[@pone.0230336.ref028]\]. A retrospective study of surgical patients by Turan and colleagues examined the association between serum vitamin D concentration and serious complications after noncardiac surgery. The authors reported an association between vitamin D concentrations and a composite of in-hospital death, serious infections, and serious cardiovascular events in patients recovering from noncardiac surgery \[[@pone.0230336.ref003]\].

A search of the literature revealed no studies of vitamin D levels in hepatobiliary surgery patients. Study of this cohort is particularly interesting as it allows comparison of vitamin D levels in cancer patients with those of previously healthy patients, such as those with cholelithiasis \[[@pone.0230336.ref002]\]. In line with the findings of Turan et al., our results demonstrate a linear inverse association between the risk of HAI and vitamin D serum levels. Moreover, both studies demonstrate an association between higher vitamin D levels and better in-hospital outcomes. However, in both studies multivariate analyses revealed no significant differences in vitamin D levels and HAIs, studied separately, as the effects were attenuated by adjustment variables \[[@pone.0230336.ref003]\]. Our multivariate analysis of HAI patients as a single group, after adjusting for sex, age, ASA score, Charlson index score, and surgery type (emergency vs planned) ([Table 4](#pone.0230336.t004){ref-type="table"}) revealed a significant decrease in risk between the first and third tertiles. Nonetheless, this effect was not observed in the model adjusted for sex, age, transfusions, vasopressors, surgery duration, and length of stay, due to the presence of a large group of patients with benign pathologies (e.g., cholelithiasis) who had a short surgery duration and short length of stay ([Table 5](#pone.0230336.t005){ref-type="table"}).

In their study of patients with health-care associated pneumonia (HCAP), Leow and colleagues \[[@pone.0230336.ref029]\] demonstrated that severe 25 (OH)D deficiency was common and was associated with a higher 30-day mortality rate than in patients with sufficient 25(OH)D levels during winter. Low vitamin D levels in ICU patients have also been linked to an increased risk of HCAP, although we observed no significant association between these 2 parameters in our study population \[[@pone.0230336.ref027]\]. Similarly, we detected no significant association between vitamin D levels and urinary tract infection (UTI), despite the fact that some authors have proposed vitamin D supplementation as a preventive measure for UTI \[[@pone.0230336.ref027]\]. ICU admission was associated with lower vitamin D levels (p = 0.005), although it should be noted that in our hospital protocol dictates that patients are admitted to ICU after certain interventions, including major hepatectomy and pancreaticoduodenectomy.

Certain limitations of our study should be noted. These include the small sample size, the potentially variable effects of sun exposure on vitamin D levels, and follow-up in outpatient clinic. Although seasonal variations can occur, serum vitamin D levels remain relatively stable over a 1-year period in most patients \[[@pone.0230336.ref030]\]. However, the mean and median vitamin D levels reported here may differ to those found in other populations and locations, particularly given the potential influence of environmental factors. In our analysis, we sought to account for the effects of multiple confounding variables in order to address this concern. Adjustments to our multivariate analysis were made to account for known confounding variables, including baseline demographics. However, we cannot rule out the existence of unknown factors that could substantially influence our results. Some of our patients received vitamin D supplementation before surgery, and it is unclear how effective these treatments may have been. Obviously, all patients diagnosed with vitamin D deficiency and insufficiency were advised to take supplementation after undergoing surgery.

In summary, our results suggest that preoperative 25(OH)D levels may constitute a modifiable risk factor for postoperative nosocomial infections in hepatobiliary surgery patients. Prospective studies should investigate the potential benefits of optimizing preoperative vitamin D status.

This study was performed at Miguel Servet Hospital, Aragon, Spain without external funding.

10.1371/journal.pone.0230336.r001
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If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Dr. Sakamuri V. Reddy

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

The authors have analyzed a large cohort of 301 patient population to evaluate the association between the levels of 25-OH vitamin D and hospital-acquired infections (HAIs) after hepatobiliary surgery. Specific comments and suggestions to further improve the manuscript are as follow. 1. Abstract- They have noted Discussion at the end, which needs to be replaced with "Conclusions" of the study. 2. (p.6; lines 133-139) delete the 'title' of the manuscript here. Also, given the previous studies in the field, the information provided "Introduction" needs to be detailed with more citations. Methods- clarify the statement that the study with patient population is approved with institutional IRB. Also, note separately a section of the "Statistical analysis" of the results. Also, note a separate paragraph on 'vitamin D' assays used to consider deficiency as per the American Endocrine Society guidelines (ex., citation \#7) in Methods. Results- please provide a clear rationale of the study undertaken given other workers findings on the subject in the field.3. p.18; line 353-Remove citation name "Youssef et al" as it belongs only to citation \#20, but it is noted as citations 6,17,20. Figure.1&2 embedded in the text are fine but seems repeated providing eps version again at the end after the References. Provide more details in the legends. I suggest the authors to follow journal article for style.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please provide additional details regarding participant consent. Since the requirement for written informed consent was waived by the ethics committee, please ensure that you have discussed whether all data collected in this study were fully anonymized before you accessed them.

3\. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a description of how participants were recruited, and d) descriptions of where participants were recruited and where the research took place.

4\. At this time, we ask that you please provide additional informatino in your Methods section about the methodology used to conduct the chemiluminescent microparticle immunoassay (CMIA) to measure vitamin D concentrations in the patients serum samples.

5\. Thank you for stating the following financial disclosure:

\"NO\"

Please provide an amended Funding Statement that declares \*all\* the funding or sources of support received during this specific study (whether external or internal to your organization) as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>.  Please state what role the funders took in the study.  If any authors received a salary from any of your funders, please state which authors and which funder. If the funders had no role, please state: \"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

6\. Thank you for stating the following in your Competing Interests section: 

\"NO\"

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state \"The authors have declared that no competing interests exist.\", as detailed online in our guide for authors at <http://journals.plos.org/plosone/s/submit-now>

This information should be included in your cover letter; we will change the online submission form on your behalf.

7\. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors' affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating "current affiliation:...." as necessary).

8\. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This manuscript by Laviano et al. describes a significant link between preoperative Vitamin-D levels and the increased chance of developing nosocomial infections in patients undergoing hepatobiliary surgery. In general this manuscript is very well-written, easy to follow and its statistical analyses are pretty complete. I would only suggests a few minor additions to the text.

1\) In line 161 authors refer previous studies similar to the submitted manuscript. It would be good to have a short explanation stating how this work in different to those.

2\) In the legend of the first table the meaning of the abbreviations (ASA, COPD) is not included.

3\) Better explanation of how the percentiles in table 1 were calculated is needed.

4\) In line 235 authors mentioned Score II, but never mentioned this score in the manuscript. A brief explanation of what this means and why it is relevant to this work will be helpful to follow the manuscript.

5\) In the third paragraph of the discussion is mentioned that other studies suggest a link between vit-D levels and heart disease. But this study does not observe statistical significance here. A possible reason for the different results should be included. Also the 4th paragraph of the discussion refers to 3rd paragraph (line 365) so the new paragraph is not really needed.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer comments:

1\. In line 161 authors refer previous studies similar to the submitted manuscript. It would be good to have a short explanation stating how this work in different to those.

A short explanation describing how this study differs to those previously published has been added to the revised manuscript.

2\. In the legend of the first table the meaning of the abbreviations (ASA, COPD) is not included.

The legend of Table 1 has been edited to include the meanings of each of the abbreviations used.

3\. Better explanation of how the percentiles in table 1 were calculated is needed.

Further information has been added to describe the process of calculating the percentiles.

4\. In line 235 authors mentioned Score II, but never mentioned this score in the manuscript. A brief explanation of what this means and why it is relevant to this work will be helpful to follow the manuscript.

Score II refers to the ASA index score. This information is now included in the methods section.

5\. In the third paragraph of the discussion is mentioned that other studies suggest a link between vit-D levels and heart disease. But this study does not observe statistical significance here. A possible reason for the different results should be included. Also the 4th paragraph of the discussion refers to 3rd paragraph (line 365) so the new paragraph is not really needed.

We have corrected the third and the fourth paragraphs of the discussion. We were unable to detect an association between cardiovascular disease and vitamin D levels due to the sample size, sample population, and study design.

###### 

Submitted filename: Response to reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0230336.r003

Decision Letter 1

Reddy

Sakamuri V.

Academic Editor

© 2020 Sakamuri V. Reddy

2020

Sakamuri V. Reddy

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

27 Feb 2020

ASSOCIATION BETWEEN PREOPERATIVE LEVELS OF 25-HYDROXYVITAMIN D AND HOSPITAL-ACQUIRED INFECTIONS AFTER HEPATOBILIARY SURGERY:  A PROSPECTIVE STUDY IN A THIRD-LEVEL HOSPITAL

PONE-D-20-02256R1

Dear Dr. Laviano,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Sakamuri V. Reddy, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0230336.r004

Acceptance letter

Reddy

Sakamuri V.

Academic Editor

© 2020 Sakamuri V. Reddy

2020

Sakamuri V. Reddy

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

4 Mar 2020

PONE-D-20-02256R1

Association between preoperative levels of 25-hydroxyvitamin D and hospital-acquired infections after hepatobiliary surgery: A prospective study in a third-level hospital

Dear Dr. Laviano:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.
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PLOS ONE Editorial Office Staff
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Dr. Sakamuri V. Reddy
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